Home > Insider Trading > Filing (0001689375-22-000039)

Filing Details

Accession Number:: 0001689375-22-000039
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-10-27 18:49:07
Reporting Period:: 2022-10-25

Accepted Time:: 2022-10-27 18:49:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689375	Entrada Therapeutics Inc.	TRDA	Pharmaceutical Preparations (2834)	813983399

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741850	Nerissa Kreher	C/O Entrada Therapeutics, Inc. 6 Tide Street Boston MA 02210	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-10-25	8,040	$2.10	28,756	No	4	M	Direct
Common Stock	Disposition	2022-10-25	4,942	$20.53	23,814	No	4	S	Direct
Common Stock	Disposition	2022-10-25	2,998	$21.42	20,816	No	4	S	Direct
Common Stock	Disposition	2022-10-25	100	$22.13	20,716	No	4	S	Direct
Common Stock	Acquisiton	2022-10-26	4,960	$2.10	25,676	No	4	M	Direct
Common Stock	Disposition	2022-10-26	643	$21.21	25,033	No	4	S	Direct
Common Stock	Disposition	2022-10-26	4,317	$22.01	20,716	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-25	8,040	$0.00	25,033	$2.10
Common Stock	Stock Option (Right to Buy)	Disposition	2022-10-26	4,960	$0.00	20,716	$2.10

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
119,682		2030-12-01	No	4	M	Direct
114,722		2030-12-01	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.01 to $21.895, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.79 to $21.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
The Form 4 filed by the reporting person on September 12, 2022 inadvertently understated the number of shares remaining subject to this option following the transactions reported therein by 111,690 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Prior to the transactions reported herein, the correct number of shares remaining subject to this option was 127,722 shares.